Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Nils Wellhausen Clear advanced filters

  • Adoptive cell therapies have emerged as promising approaches for the treatment of patients with cancer. Engineering cell therapies to confer resistance to small-molecule therapies, chemotherapies and antibody-based therapies will improve their utility and success. Here, Wellhausen, Baek and colleagues outline the key principles of engineering resistance and potential applications for haematopoietic stem cell transplantation and allogeneic immune cell therapies.

    • Nils Wellhausen
    • Joanne Baek
    • Carl H. June
    Reviews
    Nature Reviews Cancer
    Volume: 24, P: 614-628

  • The tumour microenvironment (TME) poses a significant obstacle to the success of chimeric antigen receptor (CAR) T cell immunotherapy in solid tumours. Here, the authors detail how both cellular and non-cellular components of the TME contribute to tumour resistance against CAR T cell therapy, and explore emerging strategies aimed at overcoming these barriers in order to enhance the efficacy of CAR T cell therapy.

    • Zachary L. Lamplugh
    • Nils Wellhausen
    • Yi Fan
    Reviews
    Nature Reviews Immunology
    P: 1-19

  • Immunocytokines are cytokine-based fusion proteins with therapeutic potential. New CD45-targeted immunocytokines can reprogram systemic anti-tumor immunity by prolonged retention on T cells and dendritic cells while minimizing systemic toxicities through intratumoral delivery.

    • Nils Wellhausen
    • Saar Gill
    News & Views
    Nature Immunology
    Volume: 25, P: 1775-1777